UNITED STATES
                                 SECURITIES AND EXCHANGE COMMISSION
                                              WASHINGTON, D.C. 20549


     DIVISION OF
CORPORATION FINANCE


                                                               May 9, 2019

  By E-Mail

  Andrew M. Freedman
  Olshan Frome Wolosky LLP
  1325 Avenue of the Americas
  New York, NY 10019

          Re:     MiMedx Group, Inc.
                  Soliciting Materials filed pursuant to Rule 14a-12 on May 7,
2019
                  Filed by Prescience Partners, LP, Prescience Point Special
Opportunity LP,
                    Prescience Capital, LLC, Prescience Investment Group, LLC,
Eiad
                    Asbahi, Richard J. Barry, M. Kathleen Behrens Wilsey,
Ph.D., Melvin L.
                    Keating, and K. Todd Newton
                  File No. 001-35887

  Dear Mr. Freedman:

        We have reviewed your filing and have the following comments. In some
of our comments,
  we may ask you to provide us with information so we may better understand
your disclosure.

         Please respond to this letter by amending your filing, by providing
the requested
  information, or by advising us when you will provide the requested response.
If you do not
  believe our comments apply to your facts and circumstances or do not believe
an amendment is
  appropriate, please tell us why in your response.

         After reviewing any amendment to your filing and the information you
provide in
  response to these comments, we may have additional comments.

  Soliciting Materials

  1.      Each statement or assertion of opinion or belief must be clearly
characterized as such,
          and a reasonable factual basis must exist for each such opinion or
belief. Support for
          opinions or beliefs should be self-evident, disclosed in the proxy
statement or provided to
          the staff on a supplemental basis. Provide support for your statement
that your nominees
          have "[i]mmense credibility and reputational capital," [d]emonstrated
public company
          turnaround and restatement experience," and "[e]xtensive healthcare
and biopharma
          experience and relationships."

  2.      We note the analytical report dated January 7, 2019 you filed as
soliciting materials. You
          state that the company's shares "are conservatively worth at least
$8.09" per share. The
          inclusion of valuations in soliciting materials is only appropriate
and consonant with Rule
 Andrew M. Freedman
Olshan Frome Wolosky LLP
May 9, 2019
Page 2

       14a-9 when made in good faith and on a reasonable basis and where
accompanied by
       disclosure which facilities shareholders' understanding of the basis for
and the limitations
       on the projected realizable values. See Exchange Act Release No. 16833
(May 23, 1980).
       Please provide us with your analysis supporting your valuation of the
stock and confirm
       that in future filings in which you provide a valuation you will include
a similar analysis.
       In addition, supplementally explain why your valuation is not so
qualified and subject to
       such material limitations and qualifications as to make inclusion of the
$8.09 figure
       unreasonable.

3.     Please refer to comment 1 above and provide us the support for the
following disclosure
       included in your January report:

               That the "chances of MDXG going bankrupt are remote."

               That the "majority of MDXG's sales are legitimate and
sustainable. Only a small
               portion of revenue was attributable to end-of-quarter channel
stuffing, while
               widespread bribes/kickbacks did not occur."

               That the "government is highly unlikely to levy a fine large
enough to cause
               MDXG any serious distress."

               The first and third-seventh bullet points under the caption
"Research Highlights."

               Your belief that "MDXG shareholders will enjoy a similarly
positive outcome
               once the current turmoil clears" in reference to past events at
Arthrocare and two
               other companies.

               Your belief on page 4 that "management was overly aggressive in
growing non-
               core revenue sources..."

        We remind you that the filing persons are responsible for the accuracy
and adequacy of
their disclosures, notwithstanding any review, comments, action or absence of
action by the staff

       Please direct any questions to me at (202) 551-3619.

                                                            Sincerely,

                                                            /s/ Daniel F.
Duchovny
                                                            Daniel F. Duchovny
                                                            Special Counsel
                                                            Office of Mergers
and Acquisitions